Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria

Multicenter, Open-label, Single-arm Study to Evaluate the PK, Safety, Tolerability and Efficacy of a New Artemether:Lumefantrine (2.5 mg:30 mg) Dispersible Tablet in the Treatment of Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria Identifier: NCT04300309

Novartis Reference Number: CCOA566B2307

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

This study aims to evaluate PK, safety, tolerability and efficacy of a new formulation of artemether-lumefantrine dispersible tablet in neonates and infants <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria.

Plasmodium Falciparum Malaria
Phase 2
Phase 3
Overall status 
Not yet recruiting
Enrollment count 
44 participants
Start date 
Oct 26, 2020
Completion date 
May 19, 2023
(Child, Adult, Older Adult)


artemether:lumefantrine (2.5 mg:30 mg)
artemether:lumefantrine (2.5 mg:30 mg)

Eligibility Criteria

Inclusion Criteria:

Male or female neonates/infants
Body weight <5 kg but ≥ 2 kg
In Cohort 1, infants aged >28 days; in Cohort 2, neonates aged 1 to ≤28 days (3 subgroups: 1-7 days; 8-14 days; 15-28 days)

Microscopically confirmed diagnosis of P. falciparum malaria (or mixed infections):

in Cohort 1 of ≥500 and <100,000 parasites/µL asexual P. falciparum parasitemia
in Cohort 2 of ≥100 and <100,000 parasites/µL asexual P. falciparum parasitemia
in Cohort 2, either congenital or neonatal
either symptomatic or asymptomatic

Exclusion Criteria:

Head circumference < - 2 SD z-score in cm following WHO age and sex-specific reference curves (suspicion of microcephaly)
Presence of severe malaria (according to WHO 2015 definition)

HIV status :

in Cohort 1, patient's or patient's mother's current treatment with ARV
in Cohort 2, mother's known HIV positive status at patient's birth or mother's current treatment with ARV
Presence of the following signs of a critical condition: apnea-bradycardia, sustained bradycardia, tachycardia, desaturation, hypotension, hypothermia; or other severely deteriorated general condition (based on IMCI criteria in sick infants) (WHO 2005)

Presence of any clinically significant neurological condition:

any episode of convulsion during the present illness (in keeping with the IMCI list of general danger signs)
known neurological disorders (e.g. chronic seizure disorders, cerebral palsy)
Presence of clinically significant abnormality of the hepatic and renal systems
Patients unable to swallow or whose drinking is impaired
Known hypersensitivity of the patient or either patient's parent to artemether, lumefantrine, any of the excipients of Coartem®/Riamet® Dispersible tablet, or to drugs of similar chemical classes
History of malabsorption or previous gastrointestinal surgery, or history of radiation therapy that could affect drug absorption or metabolism, or any other disorder or history of a condition that could interfere with drug absorption, distribution, metabolism, or excretion
Known family history of congenital prolongation of the QTc interval or sudden death or with any other clinical condition known to be associated with prolongation of the QTc interval such as history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease
Disturbances of electrolyte balance (e.g. hypokalaemia or hypomagnesaemia)
Presence of any age-adjusted clinically or hematologically relevant laboratory and blood chemistry abnormalities
Patients who received any antimalarial drug, including antibiotics with antimalarial activity, within 14 days of trial start, or any other prohibited drug (see Table 6-2)
Patients who received an investigational drug within 5 half-lives of enrollment or participated in an investigational study or within 30 days, whichever is longer


Novartis Pharmaceuticals
Novartis Pharmaceuticals

Have a question?

Call 1-999-669-6682 or email [email protected]